Pluripotent human stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), offer the prospect to regenerate myocardium after an infarct. To date, however, cell transplantation studies have yielded only small grafts of human cardiac muscle. Recent studies in our group and elsewhere indicate that the inclusion of stromal and vascular cells, along with cardiomyocytes, is much more effective in generating new myocardium. By transplanting pre-vascularized, engineered human myocardium, we have generated myocardial grafts that are as thick as the infarcted wall. The current proposal builds on these observations, using human cardiovascular progenitors and differentiated cells in hydrogel-based tissue engineering, to more fully regenerate the heart.
In Aim 1 we will test the ability of cardiovascular mesodermal progenitors to give rise to new myocardium in vitro and to repair the infarcted rat heart in vivo. The progenitors will be compared to "tri-cell" constructs containing hESC-derived cardiomyocytes, endothelial cells and MSCs. We hypothesize that the mesodermal progenitors will have enhanced proliferative capacity and the ability to differentiate according to environmental cues, resulting in larger grafts with greater vascular density and better integration with the host.
Aim 2 tests the responses of engineered human heart tissues to conditioning regimens of cyclic strain, electrical pacing, and varying the stiffness of their hydrogel matrix. The effects on tissue structure and electromechanical function will be assessed in vitro, and optimally conditioned constructs will be compared with unconditioned constructs for their ability to repair the infarcted heart. We also will use diffusion tensor MRI to determine if pre-aligning cardiac fibers in tissue constructs influences final fiber orientation after transplantation in the heart. These experiments will be the first to study responses of ex vivo human myocardium to changes in mechanical load or rate, and thus should provide a useful system for basic science and therapeutic screens.
In Aim 3, our optimized tissue engineering approach will be compared head- to-head vs. cell therapy, to determine which offers more promise for cardiac regeneration and restoration of ventricular function. In addition to providing important pre-clinical therapeutic information, these experiments will offer insights into fundamental aspects of human cardiovascular development.

Public Health Relevance

Much of the impact that heart disease has on society results from the heart's inability to regenerate new muscle after injury. Here we propose to use adult, embryonic and reprogrammed human stem cells to create new human heart muscle in vitro and to transplant it in vivo in animal models of heart disease. These experiments will advance our understanding of human heart development and make clinical trials of heart regeneration more feasible.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Wong, Renee P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Schools of Medicine
United States
Zip Code
Naumova, Anna V; Balu, Niranjan; Yarnykh, Vasily L et al. (2014) Magnetic Resonance Imaging Tracking of Graft Survival in the Infarcted Heart: Iron Oxide Particles Versus Ferritin Overexpression Approach. J Cardiovasc Pharmacol Ther 19:358-367
Murry, Charles E; Chong, James J H; Laflamme, Michael A (2014) Letter by Murry et al regarding article, "Embryonic stem cell-derived cardiac myocytes are not ready for human trials". Circ Res 115:e28-9
Tung, Jason C; Paige, Sharon L; Ratner, Buddy D et al. (2014) Engineered biomaterials control differentiation and proliferation of human-embryonic-stem-cell-derived cardiomyocytes via timed Notch activation. Stem Cell Reports 2:271-81
Yang, Xiulan; Rodriguez, Marita; Pabon, Lil et al. (2014) Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol 72:296-304
Chong, James J H; Yang, Xiulan; Don, Creighton W et al. (2014) Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510:273-7
Rodriguez, Marita L; Graham, Brandon T; Pabon, Lil M et al. (2014) Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J Biomech Eng 136:051005
Jiao, Alex; Trosper, Nicole E; Yang, Hee Seok et al. (2014) Thermoresponsive nanofabricated substratum for the engineering of three-dimensional tissues with layer-by-layer architectural control. ACS Nano 8:4430-9
Chong, James J H; Murry, Charles E (2014) Cardiac regeneration using pluripotent stem cells--progression to large animal models. Stem Cell Res 13:654-65
Coulombe, Kareen L K; Bajpai, Vivek K; Andreadis, Stelios T et al. (2014) Heart regeneration with engineered myocardial tissue. Annu Rev Biomed Eng 16:1-28
Lundy, Scott D; Murphy, Sean A; Dupras, Sarah K et al. (2014) Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J Mol Cell Cardiol 72:350-9

Showing the most recent 10 out of 51 publications